Transcatheter Mitral & Tricuspid Therapies

Bernard J. Zovighian
Corporate Vice President, Transcatheter Mitral & Tricuspid Therapies
Leading and transforming treatment for patients with mitral and tricuspid valve disease

Addressing the unmet needs of **large, diverse and complex patient populations**

Delivering a **portfolio of differentiated innovations** to transform care through optimal treatment and excellent outcomes

Developing **significant evidence** to change standard of care: enrolling 10 clinical studies, including 4 pivotal trials

Expect the Global opportunity to reach ~$3B by 2024 with continued longer-term growth
Many diverse and complex patients are in need of better treatment options

**DIVERSE**
- Mitral and tricuspid regurgitation are complex diseases
- No two patients are alike

**PREVALENT**
- 10+% people in the U.S. over 65 suffer from moderate or severe MR/TR

**DEADLY**
- Untreated patients have poor quality of life and high mortality rates

**UNDERTREATED**
- <2% patients receive an intervention today
TMTT is building a transcatheter-based portfolio to optimally treat this large and complex patient population

<table>
<thead>
<tr>
<th>Heart Valve</th>
<th>TRICUSPID</th>
<th>MITRAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leaflet Repair</td>
<td>PASCAL</td>
<td></td>
</tr>
<tr>
<td>Annular Reduction</td>
<td>Cardioband</td>
<td>Cardioband</td>
</tr>
<tr>
<td>Valve Replacement</td>
<td>EVOQUE</td>
<td>SAPIEN M3 EVOQUE</td>
</tr>
</tbody>
</table>
PASCAL: Investing in innovation and evidence to transform leaflet repair

**DIFFERENTIATED INNOVATION**
Enabling treatment of a broader patient population

<table>
<thead>
<tr>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple differentiating features for <strong>more effective MR reduction</strong></td>
<td>- Advance PASCAL innovations</td>
</tr>
<tr>
<td>High-touch procedural support for <strong>optimal patient outcomes</strong></td>
<td>- Continue enrollment across CLASP randomized studies</td>
</tr>
<tr>
<td><strong>Differentiated value</strong> for patients and physicians</td>
<td>- Fully enroll CLASP IID by year-end</td>
</tr>
</tbody>
</table>

- Enrolled an unprecedented 3 randomized studies:
  - CLASP IID
  - CLASP IIF
  - CLASP IITR

- Executed a disciplined European launch
  - Excellent patient outcomes
  - Site activation moderated by premium price strategy

- Executed a disciplined European launch
  - Excellent patient outcomes
  - Site activation moderated by premium price strategy

- Executed a disciplined European launch
  - Excellent patient outcomes
  - Site activation moderated by premium price strategy

- Executed a disciplined European launch
  - Excellent patient outcomes
  - Site activation moderated by premium price strategy
PASCAL: Early real-world experience replicates excellent clinical study results

**CLINICAL**

- **SAFETY**
  Freedom from serious adverse events
  - 94%

- **EFFICACY**
  at discharge
  - 96% MR ≤ 2+
  - 82% MR ≤ 1+

**REAL WORLD**

- 97%

**PASCAL**
Mitral

Average procedure time
75 mins

---

1 CLASP CE Mark Study. 2 Site Reported.
Cardioband: Investing in procedure development and innovation
Breakthrough next-generation to realize the potential of annular reduction therapy

**Differentiated Innovation**
Delivering excellent durable outcomes for certain anatomies

- **2019**
  - Individualized annular reduction with real-time confirmation
  - High-touch procedural and imaging support for optimal patient outcomes
  - Differentiated efficacy at 1 year
  - Stabilized supply
  - Initiated tricuspid EFS
  - Created centers of excellence to develop therapy and reduce procedure time

- **2020**
  - Pursue breakthrough next-gen before initiating randomized studies
  - Enroll tricuspid EFS
  - Continue procedural development

12/5/2019
Cardioband: Real world experience reflects excellent clinical study results

**Safety**
Freedom from serious adverse events

**Clinical**
- Mitral & Tricuspid: 88%

**Efficacy**
at discharge
- Mitral: 93% MR ≤ 2+
- Mitral: 79% MR ≤ 1+
- Tricuspid: 92%

**Real World**
Site Reported.

---

1 Mitral and Tricuspid CE Mark Studies, paired analyses. 2 Average Safety of Mitral and Tricuspid. 3 Site Reported.
A proven role for both repair and replacement to ensure optimal outcomes for this large, diverse patient population

Traditional surgical repair and replacement techniques
Operator-dependent outcomes, lack of Class 1 clinical evidence

<table>
<thead>
<tr>
<th>Alfieri Stitch</th>
<th>Annuloplasty</th>
<th>Chordal Repair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leaflet Resection</td>
<td>Valve Replacement</td>
<td></td>
</tr>
</tbody>
</table>

Objective: Reproducible, less invasive therapies building upon surgical insights

PASCAL
Investing in innovation and evidence in leaflet repair

Cardioband
Advancing annular reduction with breakthrough next-gen

SAPIEN M3
Accelerating safe replacement with largest transfemoral experience

EVOQUE
SAPIEN M3: Leading Transfemoral Valve Replacement
First pivotal trial for safe and effective mitral replacement

D I F F E R E N T I A T E D  I N N O V A T I O N
Bringing proven technology to mitral patients

- **Proven SAPIEN 3 valve** with 3,000+ mitral patients treated
- **Novel docking feature** allows for treatment of a wide range of annulus sizes
- **Low-profile delivery system** specifically designed for transfemoral access

**2019**
- Successful EFS experience with encouraging clinical outcomes
- Pivotal trial approved by the FDA

**2020**
- Advance next-gen innovations
- Initiate enrollment in the first FDA-approved pivotal trial of transfemoral mitral replacement
EVOQUE: Leading Transfemoral Valve Replacement
Expanding treatment options for both mitral and tricuspid patients

DIFFERENTIATED INNOVATION
Demonstrating applicability across therapeutic applications

- Unique valve and delivery system designed for mitral and tricuspid patients
- Scalable design for multiple valve sizes enabling treatment of a larger patient population
- Novel and versatile delivery system for complex anatomies

2019
- Early mitral results show excellent safety and efficacy
- Successful early tricuspid experience: 10+ patients treated at multiple centers

2020
- Continue development of next-gen innovations for both mitral and tricuspid
- Continue enrollment of mitral EFS
- Initiate tricuspid EFS

Early mitral results show excellent safety and efficacy
Successful early tricuspid experience: 10+ patients treated at multiple centers
Building clinical evidence to transform standard of care

Strong evidence is central to expanding patient treatment

4 Pivotal Studies

to transform standard of care

3 Early Feasibility Studies

to advance learnings

3 Post-Market Studies

to build real-world evidence

PASCAL Tricuspid
PASCAL DMR
PASCAL FMR
SAPIEN M3 Mitral
EVOQUE Tricuspid
Cardioband Tricuspid
EVOQUE Mitral
Cardioband Mitral
Cardioband Mitral
Driven by a dedicated, experienced team of 700+
Committed to leading and transforming treatment for patients with mitral and tricuspid valve disease

**Innovation**

4 mitral programs
3 tricuspid programs

**Clinical Evidence**

Building clinical evidence to transform standard of care
Strong evidence is central to expanding patient treatment

- 4 Pivotal studies
- 3 Post-Market Studies

Differentiated early results replicating clinical studies

**Real-World Results**

10 programs including
4 pivotal studies
2020 Underlying Global Sales Growth Outlook

Tailwinds
- Additional evidence of differentiated patient outcomes
- Increased adoption in European centers

Headwinds
- IP litigation risk
- Multiple randomized studies enrolling

Underlying Global TMTT Estimated Sales

$50M $70M

2020E
Our global TMTT strategy is designed to transform patient care

Beyond 2024

- Diverse and differentiated portfolio approved globally
- Replacement therapies and annular reduction plays a larger role
- Evidence driving patient referral and therapy adoption
- New patient standard of care for a growing unmet need
- TMTT focused on long-term leadership in mitral and tricuspid therapies